Evogene stock: Evogene joins AI roadshow. Evogene stock faces a USD 1.00 bid rule

Published on 10/22/2026 at 06:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evogene will meet U.S. investors November 2-5, 2026. For Evogene stock, Nasdaq's USD 1.00 rule runs to March 29, 2027.

Corporate milestones and market level

Evogene announced its November 2-5, 2026 AI Drug Discovery Roadshow on October 20, 2026.
Nasdaq granted Evogene 180 calendar days on September 30, 2026, with a USD 1.00 compliance threshold through March 29, 2027.
Evogene stock was last at USD 0.37 on Nasdaq on October 21, 2026, while market capitalization stood at USD 3.2 million.

EVGN, IL0011050551, Illustration mit AI erstellt.

Evogene (ISIN IL0011050551) announced on October 20, 2026, that it will join an AI drug discovery roadshow from November 2-5, 2026, according to PR Newswire. The company plans to present its ChemPass AI platform to investors, pharmaceutical companies and potential strategic partners across the U.S. East Coast.

Three events reshape the story

The latest announcement follows a corporate reset. On October 6, 2026, Evogene said it had reached a cooperation agreement with Pure Capital Group to resolve disputes and reconstitute the board, according to PR Newswire. The proposed board would comprise seven directors, while the agreement includes a 60-day standstill period.

On September 30, 2026, Evogene reported that Nasdaq had granted an additional 180 calendar days to restore compliance with its USD 1.00 minimum bid requirement. The deadline is March 29, 2027, and compliance requires a closing bid of at least USD 1.00 for ten consecutive business days, as reported by StockTitan.

What does the deadline mean?

The listing requirement remains the clearest numerical pressure point. Evogene can continue trading on Nasdaq during the cure period, but a closing bid below USD 1.00 keeps the compliance issue active and leaves a reverse share split among the company's stated alternatives.

Dates investors can track

The roadshow is scheduled for November 2-5, 2026, with stops in New York, New Jersey, Philadelphia, Washington, D.C., and Maryland. MarketBeat lists November 19, 2026, as Evogene's next estimated earnings date, while the company's investor-relations page identifies the second-quarter and first-half 2026 results as the latest reported financial release.

For investors, the roadshow offers a near-term business-development milestone, while the Nasdaq deadline supplies the harder test. The company describes itself as a computational chemistry business using generative AI to design small molecules for pharmaceutical and agricultural applications.

Stock level and company scale

EVGN was last at USD 0.37 on Nasdaq on October 21, 2026 at 4:00 p.m. ET. The same market snapshot placed its 52-week range at USD 0.35 to USD 1.33 and market capitalization at USD 3.2 million. That valuation leaves the compliance threshold well above the latest quoted level.